Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.biopha.2017.11.028 http://scihub22266oqcxt.onion/10.1016/j.biopha.2017.11.028 29156525!ä!29156525 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Pharmacother 2018 ; 97 (ä): 1356-1365 Nephropedia Template TP {{tp|p=29156525|t=2018. Esomeprazole ameliorates CCl(4) induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers |pdf=|usr=}}{{29156525}} gab.com Text Esomeprazole ameliorates CCl(4) induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers JO: Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=29156525 #FOAvip BACKGROUND: Hepatic fibrosis is a major health problem that requires further medical attention. Proton pump inhibitors are proven to possess other therapeutic potentials apart of their acid anti-secretory actions. AIM OF THE WORK: To test possible anti-fibrotic effect of esomeprazole magnesium trihydrate in management of liver fibrosis compared to silymarin, the well-known hepatoprotective agent. MATERIALS & METHODS: 40 male albino rats were divided into 4 groups: normal control group; CCl(4)-treated group (1 mL/kg 40% CCl(4), diluted in olive oil) I.P twice weekly for 6 weeks; esomeprazole-treated group (30 mg/kg body weight); and Silymarin-treated group (100 mg/kg body weight). Both esomeprazole and silymarin were given orally daily for two weeks after the last CCl(4) dose. Serum and tissue samples were assessed for histopathological and biochemical analyses. RESULTS: Esomeprazole reversed hepatocellular damage, improved liver integrity, corrected major histopathological disturbances induced by CCl(4) and lowered fibrosis scoring. It also improved anti-oxidant capacity and attenuated lipid peroxidation. Esomeprazole treatment resulted in down-regulation of hepatic pro-apoptotic Bax and up-regulation of anti-apoptotic Bcl2 protein expressions. In addition, it resulted in inhibition of TNF-alpha, TGF-beta and IL-6 -mediated inflammatory responses, and retrieval of the epithelial marker e-cadherin. CONCLUSION: Esomeprazole confers significant anti-fibrotic actions. Further study is needed to elucidate other probable mechanisms for this effect and to test their anti-fibrotic potential clinically. Twit Text FOAVip Esomeprazole ameliorates CCl(4) induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers ????Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=29156525 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29156525 #FOAvip English Wikipedia <ref>{{Cite pmid|29156525}}</ref> Esomeprazole ameliorates CCl(4) induced liver fibrosis in rats via modulating oxidative stress, inflammatory, fibrogenic and apoptotic markers #MMPMID29156525 Eltahir HM; Nazmy MH Biomed Pharmacother 2018[Jan]; 97 (ä): 1356-1365 PMID29156525show ga BACKGROUND: Hepatic fibrosis is a major health problem that requires further medical attention. Proton pump inhibitors are proven to possess other therapeutic potentials apart of their acid anti-secretory actions. AIM OF THE WORK: To test possible anti-fibrotic effect of esomeprazole magnesium trihydrate in management of liver fibrosis compared to silymarin, the well-known hepatoprotective agent. MATERIALS & METHODS: 40 male albino rats were divided into 4 groups: normal control group; CCl(4)-treated group (1 mL/kg 40% CCl(4), diluted in olive oil) I.P twice weekly for 6 weeks; esomeprazole-treated group (30 mg/kg body weight); and Silymarin-treated group (100 mg/kg body weight). Both esomeprazole and silymarin were given orally daily for two weeks after the last CCl(4) dose. Serum and tissue samples were assessed for histopathological and biochemical analyses. RESULTS: Esomeprazole reversed hepatocellular damage, improved liver integrity, corrected major histopathological disturbances induced by CCl(4) and lowered fibrosis scoring. It also improved anti-oxidant capacity and attenuated lipid peroxidation. Esomeprazole treatment resulted in down-regulation of hepatic pro-apoptotic Bax and up-regulation of anti-apoptotic Bcl2 protein expressions. In addition, it resulted in inhibition of TNF-alpha, TGF-beta and IL-6 -mediated inflammatory responses, and retrieval of the epithelial marker e-cadherin. CONCLUSION: Esomeprazole confers significant anti-fibrotic actions. Further study is needed to elucidate other probable mechanisms for this effect and to test their anti-fibrotic potential clinically. |Administration, Oral[MESH] |Animals[MESH] |Antioxidants/metabolism[MESH] |Apoptosis/drug effects[MESH] |Carbon Tetrachloride/toxicity[MESH] |Disease Models, Animal[MESH] |Down-Regulation/drug effects[MESH] |Esomeprazole/administration & dosage/*pharmacology[MESH] |Inflammation/drug therapy/pathology[MESH] |Lipid Peroxidation/drug effects[MESH] |Liver Cirrhosis/*prevention & control[MESH] |Male[MESH] |Oxidative Stress/*drug effects[MESH] |Protective Agents/administration & dosage/pharmacology[MESH] |Proton Pump Inhibitors/administration & dosage/pharmacology[MESH] |Rats[MESH] |Silymarin/administration & dosage/*pharmacology[MESH]Esomeprazole ameliorates CCl(4) induced liver fibrosis in rats via mod(epmc).pdf DeepDyve Pubget Overpricing